Small-molecule senolytic compounds targeting BCL-xL were beneficial in a mouse model of diabetic edema and well tolerated when tested in a phase 1 trial involving eight patients with diabetic macular edema.
- Sergio Crespo-Garcia
- Frédérik Fournier
- Przemyslaw Sapieha